Comparison of technetium-99m-MIBI and thallium-201-chloride uptake in primary thyroid lymphoma

Autor: Andrew Scott, Kostakoglu L, Brien Jp, O., Dj, Straus, Hm, Abdel-Dayem, Sm, Larson

Publikováno v: Europe PubMed Central

A case of primary thyroid lymphoma demonstrating uptake of 99mTc-hexakis-2-methoxy isobutyl isonitrile (MIBI) is presented. The 99mTc-MIBI image more clearly delineated the extent of tumor as demonstrated on CT compared to 201Tl-chloride and [99mTc]p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::7f342853fd12a9fb998a2a08b5aa2e26
https://pubmed.ncbi.nlm.nih.gov/1613584

Erratum to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.

Autor: Epstein-Peterson ZD; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Drill E; Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY., Aypar U; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY., Batlevi CL; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Caron P; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Dogan A; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY., Drullinsky P; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Gerecitano J; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Hamlin PA; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Ho C; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY., Jacob A; Adaptive Biotechnologies, Seattle, WA., Joseph A; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Laraque L; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Matasar MJ; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Moskowitz AJ; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Moskowitz CH; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Mullins C; Adaptive Biotechnologies, Seattle, WA., Owens C; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Salles G; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Schöder H; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Straus DJ; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Younes A; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Zelenetz AD; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Kumar A; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. kumara@mskcc.org.

Publikováno v: Haematologica [Haematologica] 2024 Aug 01; Vol. 109 (8), pp. 2749-2752. Date of Electronic Publication: 2024 Aug 01.

Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.

Autor: Epstein-Peterson ZD; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Drill E; Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center., Aypar U; Department of Pathology, Memorial Sloan Kettering Cancer Center., Batlevi CL; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Caron P; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Dogan A; Department of Pathology, Memorial Sloan Kettering Cancer Center., Drullinsky P; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Gerecitano J; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Hamlin PA; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Ho C; Department of Pathology, Memorial Sloan Kettering Cancer Center., Jacob A; Adaptive Biotechnologies, Seattle, WA., Joseph A; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Laraque L; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Matasar MJ; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Moskowitz AJ; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Moskowitz CH; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Mullins C; Adaptive Biotechnologies, Seattle, WA., Owens C; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Salles G; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Schöder H; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY., Straus DJ; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Younes A; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Zelenetz AD; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Kumar A; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center. kumara@mskcc.org.

Publikováno v: Haematologica [Haematologica] 2024 Apr 01; Vol. 109 (4), pp. 1149-1162. Date of Electronic Publication: 2024 Apr 01.

TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy.

Autor: Johnson WT; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY., Ganesan N; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY., Epstein-Peterson ZD; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY., Moskowitz AJ; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY., Stuver RN; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY., Maccaro CR; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY., Galasso N; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY., Chang T; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY., Khan N; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY., Aypar U; Department of Pathology, Cytogenetics Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY., Lewis NE; Department of Pathology, Hematopathology Service, Memorial Sloan Kettering Cancer Center, New York, NY., Zelenetz AD; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY., Palomba ML; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY., Matasar MJ; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY., Noy A; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY., Hamilton AM; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY., Hamlin P; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY., Caron PC; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY., Straus DJ; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY., Intlekofer AM; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY., Lee Batlevi C; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY., Kumar A; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY., Owens CN; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY., Sauter CS; Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH., Falchi L; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY., Lue JK; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY., Vardhana SA; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY., Salles G; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY., Dogan A; Department of Pathology, Hematopathology Service, Memorial Sloan Kettering Cancer Center, New York, NY., Schultz ND; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY., Arcila ME; Department of Pathology, Molecular Diagnostic Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY., Horwitz SM; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY.

Publikováno v: Blood advances [Blood Adv] 2023 Sep 12; Vol. 7 (17), pp. 5172-5186.

Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical Setting.

Autor: Zheng S; Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA., Gupta K; New York Medical College, Valhalla, NY 10595, USA., Goyal P; College of Osteopathic Medicine, Touro University California, Vallejo, CA 94592, USA., Nakajima R; Memorial Sloan Kettering Cancer Center, Department of Radiology, New York, NY 10065, USA., Michaud L; Memorial Sloan Kettering Cancer Center, Department of Radiology, New York, NY 10065, USA., Batlevi CL; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA., Hamlin PA; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA., Horwitz S; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA., Kumar A; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA., Matasar MJ; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA., Moskowitz AJ; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA., Moskowitz CH; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA.; Sylvester Cancer Center, University of Miami, Miami, FL 33136, USA., Noy A; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA., Palomba ML; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA., Straus DJ; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA., Von Keudell G; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA., Falchi L; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA., Yahalom J; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA., Zelenetz AD; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA., Younes A; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; AstraZeneca, 1800 Concord Pike, Wilmington, DE 19803, USA., Salles G; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA., Schöder H; Memorial Sloan Kettering Cancer Center, Department of Radiology, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA., Joffe E; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA.

Publikováno v: Cancers [Cancers (Basel)] 2023 Mar 14; Vol. 15 (6). Date of Electronic Publication: 2023 Mar 14.